Iovance Biotherapeutics Inc
Company Profile
Business description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Contact
825 Industrial Road
Suite 100
San CarlosCA94070
USAT: +1 650 260-7120
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
975
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
stocks
ASX top pick remains cheap with narrowing brand focus
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,857.00 | 48.10 | 0.55% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,407.96 | 157.94 | -0.64% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 64,179.27 | 1,237.36 | -1.89% |
| NZX 50 Index | 13,180.02 | 73.63 | -0.56% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,653.30 | 61.90 | 0.72% |
| SSE Composite Index | 3,993.23 | 16.80 | -0.42% |